['diabetes', 'diabetes mellitus, type 1']
['nnc0114-0006', 'liraglutide', 'placebo']

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  T1DM (type 1 diabetes mellitus) (as diagnosed clinically) for not more than 20 weeks
             prior to screening - Male or female, aged 18-45 (both inclusive) at the time of
             signing the informed consent form

          -  Non-fasting peak C-peptide higher or equal to 0.2 nmol/l at visit 2

          -  BMI (body mass index) higher or equal to 18.5 kg/m^2

          -  Presence of one or more islet specific auto antibodies (glutamic acid decarboxylase
             (GAD), islet antigen-2 (IA2) or zinc-transporter 8 (ZnT8)) at screening

          -  Insulin dependence unless in temporary spontaneous remission (honeymoon period)

        Exclusion Criteria:

          -  Daily insulin usage above 1 U/kg per day at screening or use of continuous
             subcutaneous insulin infusion (CSII)

          -  History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic
             infections or conditions predisposing to chronic infections (e.g., bronchiectasis and
             chronic osteomyelitis)

          -  History of severe systemic fungal infection within the past 12 months prior to
             screening unless treated and resolved with appropriate documented therapy

          -  Vaccination within 4 weeks before randomisation, Visit 3 (V3)

          -  Receipt of any other concomitant medications or herbal products that can influence the
             immune system within 90 days prior to screening (V1)

          -  History of pancreatitis (acute or chronic)

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary
             Thyroid Carcinoma (MTC)

          -  Any past or current diagnosis of malignant neoplasms

          -  Known impairment of the immune system, except for T1DM, coeliac disease, alopecia,
             autoimmune antibodies not considered clinical important (e.g. thyroid antibodies
             without any clinically important thyroid disease), and vitiligo
      